Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CANbridge Life Sciences Ltd.

www.canbridgepharma.com

Latest From CANbridge Life Sciences Ltd.

GC Pharma Hones R&D Focus, Tweaks US Immunoglobulin Strategy

Leading South Korean pharma firm GC Pharma realigns R&D priorities and resources and changes US strategy amid delayed approval of its immunoglobulin product.

South Korea Research & Development

Asia Deal Watch: Antibody-Drug Conjugates Reign With Alliances Involving Celltrion, Miracogen & WuXi Biologics

Celltrion and iProgen will co-develop ADC candidates, Miracogen and Synaffix sign a technology license after a successful research collaboration, and WuXi will provide clinical trial material to NBE Therapeutics.

Deals Commercial

Orphan Drug Makers Get Selected Tax Breaks As China Turns To Access

Following anticancer drugs, rare disease treatments become the latest products in China’s to get value added tax reductions. Orphan drug makers can breath easier, but much more is needed, industry insiders say.

China Rare Diseases

Rare But Real: How One Startup Is Willing Itself To Lift China Orphan Drug Market

As a promising market for orphan drugs, China has seen several approvals in this space in the past six months, mostly from multinationals. But Beijing-based CANbridge believes that a smaller biotech also has a good shot at a leadership role, despite a lack of funding and reimbursement and prickly pricing issues.

China Rare Diseases
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • In Vitro Diagnostics
  • Medical Devices
  • Pharmaceuticals
    • Specialty Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • China
  • Parent & Subsidiaries
  • CANbridge Life Sciences Ltd.
  • Senior Management
  • James Xue, PhD, CEO
    Glenn Hassan, CFO & CBO
    Gerald F Cox, MD, PhD, Interim CMO
  • Contact Info
  • CANbridge Life Sciences Ltd.
    Phone: 10 84148018
    Timeloit, No. 17 RongChuang Rd.
    Ste. 301, 3F
    Beijing, 100102
    China
Advertisement
Advertisement
UsernamePublicRestriction

Register